Education and awareness program targeting the assessment of adherence of the treatment of dyslipidemia - PRECAVER

Exclusion Criteria

• Pregnancy and childbearing
• ·History of severe hypersensitivity (including myopathy) to other HMG-CoA reductase inhibitors.
• ·Subjects with indication of use of cyclosporine and other associations of other lipid lowering drugs.
• ·Subjects with underlying diseases that may influence lipid levels (i.e. uncontrolled hypothyroidism defined as a Thyroid stimulating hormone (TSH) > 1.5 times upper level of normality (ULN) at Visit 1, AIDS, transplanted subjects, etc).
• ·History of drug and alcohol abuse.
• ·Current active liver disease or hepatic failure or elevations in ALT >3 times the ULN.
• ·Elevation of CPK > 3 times the ULN.
• ·Elevation in the seric creatinine > 2,0 mg / dL.
• ·History of malignancy in the last 5 years, except basal cell or squamous cell carcinoma of the skin (women with a history of Cervical dysplasia must be included, unless they have t3 clear consecutive Papanicolaou (Pap) smears , before the entry in the study).
• ·Any other known clinical condition that, in the opinion of the investigator, may compromise the subject's safety.